Antibody and Plasmablast Response to 13-Valent Pneumococcal Conjugate Vaccine in Chronic Lymphocytic Leukemia Patients – Preliminary Report
Table 1
(a) Characteristics of CLL patients and control group. (b) Percentages of plasmablasts and serum anti-pneumococcal antibody as well as IgG2 levels before and after PCV13 vaccination in the CLL patients and control group.